Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura by F. Peyvandi et al.
chronic lymphocytic leukemia (CLL): dissecting the contribution of
17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a
prospective clinical trial. Blood. 2009;114(13):2589-97.
14. Zenz T, Habe S, Denzel T, Winkler D, Dohner H, Stilgenbauer S.
How little is too much? p53 inactivation: from laboratory cutoff to
biological basis of chemotherapy resistance. Leukemia. 2008;
22(12):2257-8. 
15. Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Giné E, Bosch
F. How I treat refractory CLL. Blood. 2006;107(4):1276-83.
16. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J,
et al. Indications for allogeneic stem cell transplantation in chronic
lymphocytic leukemia: the EBMT transplant consensus. Leukemia.
2007;21(1):12-7.
17. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S,
et al. Comprehensive assessment of genetic and molecular features
predicting outcome in patients with chronic lymphocytic leukemia:
results from the US Intergroup Phase III Trial E2997. J Clin Oncol.
2007;25(7):799-804.
18. Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, et al.
Prognostic factors identify 3 risk groups in the LRF CLL4 trial, inde-
pendent of treatment allocation. Haematologica. 2010 May 29. [Epub
ahead of print]
19. Stilgenbauer S, Eichhorst BF, Busch R, Zenz T, Winkler D, Buhler A,
et al. Biologic and clinical markers for outcome after fludarabine (F) or
F plus cyclophosphamide (FC) - comprehensive analysis of the CLL4
trial of the GCLLSG. ASH Annual Meeting Abstracts. 2008;112:2089.
20. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al.
Early results of a chemoimmunotherapy regimen of fludarabine,
cyclophosphamide, and rituximab as initial therapy for chronic lym-
phocytic leukemia. J Clin Oncol. 2005;23(18):4079-88.
21. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G,
Dohner H, et al. Guidelines for the diagnosis and treatment of chron-
ic lymphocytic leukemia: a report from the International Workshop
on Chronic Lymphocytic Leukemia updating the National Cancer
Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-
56.
22. Best OG, Gardiner AC, Davis ZA, Tracy I, Ibbotson RE, Majid A, et
al. A subset of Binet stage A CLL patients with TP53 abnormalities
and mutated IGHV genes have stable disease. Leukemia. 2009;
23(1):212-4.
Editorials and Perspectives
1444 haematologica | 2010; 95(9)
Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura
Flora Peyvandi, Roberta Palla, Luca A. Lotta
A. Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialties, Fondazione IRCCS Ca’
Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano and Luigi Villa Foundation, Milan, Italy
E-mail: flora.peyvandi@unimi.it doi:10.3324/haematol.2010.027169
(Related Original Article on page 1555)
Thrombotic thrombocytopenic purpura (TTP) is a rare
thrombotic disease characterized by episodes of throm-
bocytopenia and microangiopathic hemolytic anemia
due to disseminated microvascular thrombosis. TTP was
first described in 1924 by Moschowitz as a disease pre-
senting with a pentad of signs and symptoms (anemia,
thrombocytopenia, fever, hemiparesis and hematuria).1
Post-mortem examination showed widespread thrombi,
mainly composed of platelets, in the terminal circulation
of several organs. The description of von Willebrand fac-
tor (VWF) multimers of unusually large size in the plas-
ma of patients with TTP represented a turning point for
the understanding of the disease pathophysiology.2,3 The
presence in plasma of the highly platelet-adhesive
unusually large multimers of VWF provided a plausible
explanation for the platelet- and VWF-rich thrombi
observed in the small vessels of patients with TTP.
Studies in the late 1990s then independently demonstrat-
ed the severe deficiency of a specific VWF cleaving-pro-
tease in the plasma of patients with recurrent TTP.4 This
protease was identified as the thirteenth member of the
ADAMTS (a disintegrin and metalloprotease with
thrombospondins 1 repeats) family of metalloproteases,
ADAMTS13.5-7 Severe ADAMTS13 deficiency can be
due to mutations in the ADAMTS13 gene (congenital
TTP)8 or to anti-ADAMTS13 autoantibodies (autoim-
mune TTP).9-11 The antibody-mediated severe deficiency
of ADAMTS13 can be detected in most patients with
idiopathic TTP (i.e. TTP occurring without associated
clinical conditions/events), whereas its prevalence is
much lower in the secondary forms of TTP (i.e. TTP
associated with pregnancy, infections, autoimmune dis-
eases and the use of drugs such as ticlopidine and clopi-
dogrel).12,13 It should also be mentioned that there are
idiopathic cases of TTP with only slightly deficient or
even normal ADAMTS13 levels at presentation, but
these cases are not object of the present article in which
idiopathic and autoantibody-mediated TTP are used as
synonyms.
Epidemiology and clinical course of idiopathic 
thrombotic thrombocytopenic purpura
The incidence of idiopathic TTP is estimated to be 4.5/1
million person/years, being higher in blacks. The male to
female ratio is 1:2, similarly to the ratio for other autoim-
mune diseases.14 The acute prognosis of idiopathic, anti-
body-mediated TTP tends to be less severe, but the risk of
recurrent disease is higher than that of secondary
forms.15,16 The overall mortality of TTP was higher than
90%, but has decreased to 8-30% after the introduction of
plasma exchange, which is the treatment of choice of
acute TTP episodes.17-20 The lower mortality of patients
with idiopathic TTP (21% versus 39% in the frame of the
Oklahoma TTP registry16) is probably due to the higher
response to plasma exchange of patients with autoanti-
bodies and to the mortality related to associated condi-
tions in secondary cases.21 Up to 40% of patients with
TTP develop recurrent episodes of the disease, with the
risk of recurrences being higher in patients with severe
ADAMTS13 deficiency and anti-ADAMTS13 autoanti-
bodies during acute episodes.15,16,22-24 The cumulative risk
of recurrence at 7.5 years after the first episode in patients
with ADAMTS13 activity below 10% at presentation was
estimated to be 41%, 10 times that of patients with activ-
ity above 10% (4% risk at 7.5 years).16 Persistence of
ADAMTS13 deficiency and of autoantibodies during dis-
ease remission is also associated with increased risk of
recurrence.25,26
Characterization of anti-ADAMTS13 antibodies
Anti-ADAMTS13 autoantibodies have been the focus
of several research efforts trying to characterize their
immunoglobulin (Ig) subclass, specificity and mecha-
nisms of action. Early studies distinguished two classes
of anti-ADAMTS13 autoantibodies: inhibitory and non-
inhibitory antibodies. Inhibitory antibodies are present
in 50-90% and their mechanism of action is the inhibi-
tion of ADAMTS13-mediated proteolysis of VWF.27
When non-inhibitory antibodies are also measured, anti-
ADAMTS13 autoantibodies are detectable in 97-100%
of patients.27,28 The core binding site for VWF, located in
the spacer domain of ADAMTS13 and consisting of
amino acid residues Tyr572-Asn579 and Arg657-Gly666,
represents the target site of the autoantibodies found in
the plasma of several TTP patients.29,30 The mechanism of
action of non-inhibitory antibodies has been proposed to
be opsonisation and enhanced clearance of ADAMTS13,
but this has never been proven.27,28 Studies on the class of
anti-ADAMTS13 autoantibodies showed they are usual-
ly of IgG type, particularly IgG1 and IgG4 subtypes,10,31
but in a few cases autoantibodies of IgA and/or IgM iso-
type were also found.28,32 Most anti-ADAMTS13 IgG
found in TTP patients were demonstrated to be directed
against the spacer domain, but additional antibodies
against other ADAMTS13 domains were also detect-
ed.33,34 However, these studies were conducted in small
cohorts of patients. In this issue of Haematologica,
Zheng et al.35 present the first study of antibody specifici-
ty on a relatively large group of patients with TTP, find-
ing that, although almost all patients with IgG had anti-
bodies directed against the N-terminal ADAMTS13
domains (Cys-rich through spacer), where the catalytic
site of ADAMTS13 is located, up to 46% of TTP patients
also had antibodies against C-terminal ADAMTS13
domains (TSP1-5 through CUB). Moreover, two patients
had antibodies only against C-terminal domains of
ADAMTS13, but not against N-terminal domains. These
findings suggest a functional role of C-terminal domains
of ADAMTS13 in vivo, also in light of the importance of
these domains in the VWF-ADAMTS13 interaction
under fluid shear stress. Importantly, Zheng et al.35 corre-
lated antibody specificity with clinical data, showing
that patients with antibodies against ADAMTS13 C-ter-
minal domains had lower platelet counts at presentation.
This is not the first time that anti-ADAMTS13 anti-
body features have been found to correlate with clinical
outcomes in TTP. Patients with IgG subclasses 4 were
found to be more likely to have disease recurrence than
patients with IgG subclass 1.31 Patients with high
inhibitor titers were found to have worse acute-disease
prognosis.31 Consistently, patients with high levels of IgG
(both inhibitory and non-inhibitory) were found to have
a higher likelihood of developing cardiac involvement
and, hence, a poorer prognosis in comparison to patients
with low IgG levels.36 All these findings indicate that dif-
ferent antibody features might be associated with clini-
cal outcomes in TTP, but more comprehensive studies
should be carried out before antibody characterization
can be introduced into routine clinical practice of TTP.
Moreover, other questions remain to be addressed.
Acquired TTP is surely an autoimmune disorder, at
least in those patients with an autoantibody-mediated
severe ADAMTS13 deficiency, but the mechanisms
involved in the loss of tolerance of the immune system
against ADAMTS13 are still unknown. The higher inci-
dence of autoimmune idiopathic TTP in specific ethnic
groups such as Afro-Caribbeans, as well as the report of
idiopathic TTP in two monozygotic twins who both
developed anti-ADAMTS13 antibodies,37 strongly argue
for a genetic predisposition even in the acquired form of
the disease. In the last year two groups independently
demonstrated an association between human leukocyte
antigen (HLA) alleles and idiopathic TTP: HLA-DR and
HLA-DQ typing suggests an underlying genetic risk for
the development of TTP in Europeans.38,39 As for the anti-
body characterization, confirmation of these results in
larger groups of patients and in other ethnic groups are
required prior to the introduction of HLA typing in the
control of the disease. 
Treatment and clinical trials in idiopathic thrombotic
thrombocytopenic purpura 
Plasma exchange remains the treatment of choice for
acute episodes of TTP.40 As mentioned, its introduction
greatly reduced the disease mortality and it has been
proven superior to plasma infusion.18 Several different
immunosuppressive drugs (corticosteroids, cyclosporine,
azathioprine and, recently, rituximab) are added to plasma
exchange by many centers, with the rationale that these
Editorials and Perspectives
haematologica | 2010; 95(9) 1445
Table 1. Features of novel drugs that could potentially be used in idiopathic thrombotic thrombocytopenic purpura along with plasma exchange.
Drug(s) Pathogenic mechanism Drug class Mechanism of action Stage of development
Rituximab. Other drugs Production of anti-ADAMTS13 Anti-CD20 antibodies B-lymphocyte depletion Available
under development auto antibodies
Recombinant ADAMTS13 Impaired VWF cleavage Recombinant Replacement of deficient Pre-clinical development
replacement products ADAMTS13
Aptamer ARC1779 VWF binding to platelets VWF-platelet interaction Blockage of VWF-mediated Phase 2 clinical trial has been
(Archemix Corp) and VWF-mediated thrombosis inhibitors platelet aggregation terminated since it was not 
possible to complete 
enrollment within a reasonable 
period of time
Nanobody ALX-0681 (Ablynx) VWF binding to platelets VWF-platelet interaction Blockage of VWF-mediated  Phase 2 clinical study under 
and VWF-mediated thrombosis inhibitors platelet aggregation development
drugs help to stop antibody production in autoimmune
cases, but their efficacy has never been confirmed by a
large clinical trial. In addition to these treatments, novel
drugs have been developed or are undergoing pre-clinical
development for potential use in idiopathic TTP along
with plasma exchange. These could tackle different
aspects of TTP pathophysiology (Table 1).  First, it is pos-
sible to reduce or abolish the production of anti-
ADAMTS13 autoantibodies with anti-CD20 monoclonal
antibodies that target B-lymphocytes (e.g. rituximab, but
other more potent compounds are being developed).41,42
Second, in principle, it could be possible to restore VWF
cleavage in patients with severe ADAMTS13 deficiency
with the use of recombinant ADAMTS13. Third, novel
compounds that inhibit VWF binding to platelet glycopro-
tein Ib-alpha have been developed and could block VWF-
mediated platelet activation. There is hope in the TTP
community that these novel therapeutic strategies will be
able to reduce the persistently high disease mortality.
However, the availability of these new options entails a
burden of new challenges for clinicians who have to deal
with TTP patients, including uncertainties on the safety of
the drugs in a delicate clinical setting such as that of a TTP
patient during an acute episode and on the subgroup(s) of
patients (idiopathic, secondary, TTP with prominent renal
impairment, etc.) who could benefit from the treatment.
The efficacy and safety of these novel therapeutic
strategies will need to be assessed in the frame of large
clinical trials, a challenge for clinical scientists who work
on this rare disease. The incidence of idiopathic TTP is
such that any consortium willing to carry out a 3-year clin-
ical trial involving roughly 100 patients would need to be
able to cover a population of 66 million people (assuming
an incidence of 4.5/1 million person/years). The choice of
the clinical end-point is another challenge: mortality is
approximately 20% which makes it a hardly targetable
end-point. Surrogate end-points such as the incidence of
stroke, renal failure, myocardial infarction, time to platelet
recovery or clinical remission may be adequate for the def-
inition of therapeutic efficacy but there are few data avail-
able from cohort studies that could inform the design of
clinical trials employing these end-points. The picture is
made even more complicated by the heterogeneity in the
pathophysiological background of TTP. The inclusion in a
TTP trial of secondary cases, patients with atypical
hemolytic uremic syndrome, patients with a first TTP
episode or recurrence may in principle conceal the effect
of a treatment which is highly effective in a subgroup of
TTP patients (e.g. only those with anti-ADAMTS13
autoantibodies). Recently, a phase 2, double-blind, place-
bo-controlled, clinical trial of intravenous ARC1779, an
inhibitor of VWF binding to platelet glycoprotein Ib-α,
was stopped due to slow recruitment (clinicaltrials.gov
identification number NCT00726544). New trials are
nonetheless being designed and carried out. These will be
critical to the efforts of translating preclinical achieve-
ments into improvements in the care of this rare, but yet
(and still) life-threatening thrombotic disease.  
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Hematopoietic stem cell donors: rethinking traditional
choices
From the time of the first successful experiences of allo-
geneic bone marrow transplantation,1,2 and during the long
previous history of failure,3 it became clear that HLA-iden-
tity/compatibility between donor and recipient was an
essential condition for the success of the transplant. Such
compatibility is constantly found in homozygous twins
(who also have identical minor histocompatibility anti-
gens) and statistically in 25% of siblings. This HLA-com-
patibility was a necessary condition for the desired cre-
ation of a “biological chimera”; but transplant tolerance
had to be promoted by lowering the recipient’s immune
response to prevent rejection, at least unless the patient
was not seriously immunocompromised as, for example,
in some cases of severe combined immunodeficiency. In
particular, the use of total body irradiation since 1959, of
cyclophosphamide since 1972, and of the combined use of
both of these since 1974 are recognized as historical land-
marks. Even after an HLA-compatible transplant, it was
